A collaborative research project undertaken by the University of Melbourne, the Oxford University Clinical Research Unit in Viet Nam (OUCRU) and the Wellcome Trust Sanger Institute has led to the analysis of the largest genetically decoded collection of the bacterial pathogen Klebsiella pneumoniae, which causes a spectrum of diseases in humans and animals. This analysis has revealed the impact of antibiotic treatment on its population structure and provides the tools needed to track this important pathogen.
The recent earthquakes in Nepal, on the 25th April and 12th May 2015, have caused a tragic loss of life and had a devastating impact on an already fragile infrastructure. The resilience of the people of Nepal is legendary but the challenges are enormous. The initial focus was on finding survivors and ensuring essential food, water and safe ...
Experts have raised a global health alert after a lethal strain of typhoid spread across Asia and Africa. The rise of antibiotic-resistant typhoid is driven by a single clade or “family” of the bacteria that cause the disease known as H58, researchers have found. Co-author Dr Stephen Baker, from the Hospital for Tropical Diseases, an Oxford University clinical research unit in Ho Chi Minh City, Vietnam, said: “These results reinforce the message that bacteria do not obey international borders and any efforts to contain the spread of antimicrobial resistance must be globally co-ordinated.”
NDM are pleased to be able to announce that we have successfully achieved the Silver Athena SWAN award. The Athena SWAN Charter recognises and celebrates good practice on recruiting, retaining and promoting women in science, technology, engineering, maths and medicine (STEMM) in higher education.
A vaccine against Malaria, trialed at the Kenya Medical Research Institute (KEMRI), has shown promising results in its first test. The trial in Kenya found that the vaccine was 67% effective against Plasmodium falciparum infections - see BBC report.
Claudia Turner, Senior Research Paediatrician at the Cambodia Oxford Medical Research Unit (COMRU), begins on 21 April as Strategic Director for the Angkor Hospital for Children (AHC), where COMRU is hosted in Siem Reap. "I am very excited to be taking up such a challenging role at the Angkor Hospital for Children, an amazing institution that ...
Initial results from the Phase 1 trial for the rVSV ZEBOC candidate Ebola vaccine have now been published. The trial found that the candidate vaccine had no serious side effects although some volunteers experienced fever for the first few days after vaccination, and some developed transient pain and/or swelling of their joints. The candidate vaccine was able to raise antibody responses that neutralized Ebola-like virus particles in the laboratory.
The trial team in Kilifi was led by Dr. Patricia Njuguna with support from Prof Philip Bejon and Dr Benjamin Tsofa. Although there are no cases of Ebola reported in Kenya, demonstrating safety and immune responses by the vaccine in the Kenyan population will facilitate use of the vaccine if necessary.
On March 24th 1882, Dr Robert Koch announced that he had discovered the cause of tuberculosis (TB). 24th March is ‘World Tuberculosis Day’ - an opportunity to raise awareness about the burden of TB worldwide.
Although not that common in the UK (there were 7,892 recorded cases in the UK in 2013), TB is still a big problem in other parts of the world. NDM spoke to Professor Guy Thwaites, Director of theOxford Clinical Research Unit in Vietnam, about the situation in South-east Asia and the ongoing research at OUCRU in to eradicating the disease and improving patient outcomes.
There is an increasing body of evidence to suggest that significant quantities of medicines and medical products, especially in low and middle-income countries, are of poor quality. Malaria researcher and drug quality expert Professor Paul Newton, of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit in Laos, explains the latest research findings and explores some of the recommendations to improve medicine provision for clinical trials.
Recent reports suggest that artemisinin drug resistance is emerging and spreading in many parts of the Asian Mekong region.
A study published today by NDM researchers in Lancet Infectious Diseases reports that the spread of artemisinin drug resistance is following the same historical route as resistance to other antimalarial drugs, chloroquine and sulfadoxine/pyrimethamine.